[EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS [FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS GAMMA-T DU RÉCEPTEUR ORPHELIN APPARENTÉ AUX RÉCEPTEURS DES RÉTINOÏDES (ROR) )
[EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS [FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS GAMMA-T DU RÉCEPTEUR ORPHELIN APPARENTÉ AUX RÉCEPTEURS DES RÉTINOÏDES (ROR) )
The present invention provides a heterocyclic compound having a RORγt inhibitory action.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the specification.
or a salt thereof.
The present invention provides a heterocyclic compound having a RORγt inhibitory action.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the specification.
or a salt thereof.
Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors
申请人:Takeda Pharmaceutical Company Limited
公开号:US10093629B2
公开(公告)日:2018-10-09
Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS
申请人:Takeda Pharmaceutical Company Limited
公开号:US20170144973A1
公开(公告)日:2017-05-25
Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.